Secondary Pulmonary Alveolar Proteinosis Complicated by Hemophagocytic Syndrome in a Patient with Adult-onset Still's disease: A Case-based Review

Intern Med. 2026 Jan 15;65(2):331-336. doi: 10.2169/internalmedicine.5421-25. Epub 2025 Jul 3.

Abstract

Treatment of secondary pulmonary alveolar proteinosis (SPAP) focuses on managing the underlying disease, typically myelodysplastic syndrome. However, immunosuppressive therapy may worsen the condition in autoimmune disease-associated SPAP. We report the case of a 74-year-old woman with hemophagocytic syndrome and adult-onset Still's disease, who developed ground-glass opacities and consolidations during immunosuppressive treatment. SPAP was confirmed by a biopsy and negative for anti-granulocyte-macrophage colony-stimulating factor antibodies. Although whole-lung lavage was considered if SPAP worsened significantly, no further deterioration was observed with tapering of prednisolone. A literature review and details of this case highlight the importance of attenuating immunosuppressive therapy, rather than its intensification, for SPAP in autoimmune diseases.

Keywords: hemophagocytic syndrome; immunosuppressive therapy; pulmonary alveolar proteinosis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Lymphohistiocytosis, Hemophagocytic* / complications
  • Lymphohistiocytosis, Hemophagocytic* / diagnosis
  • Prednisolone / adverse effects
  • Prednisolone / therapeutic use
  • Pulmonary Alveolar Proteinosis* / complications
  • Pulmonary Alveolar Proteinosis* / diagnosis
  • Pulmonary Alveolar Proteinosis* / etiology
  • Still's Disease, Adult-Onset* / complications
  • Still's Disease, Adult-Onset* / diagnosis
  • Still's Disease, Adult-Onset* / drug therapy

Substances

  • Prednisolone
  • Immunosuppressive Agents